1. Home
  2. MNDY vs ACAD Comparison

MNDY vs ACAD Comparison

Compare MNDY & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo monday.com Ltd.

MNDY

monday.com Ltd.

HOLD

Current Price

$81.55

Market Cap

3.7B

Sector

Technology

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$25.59

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNDY
ACAD
Founded
2012
1993
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.8B
IPO Year
2021
2000

Fundamental Metrics

Financial Performance
Metric
MNDY
ACAD
Price
$81.55
$25.59
Analyst Decision
Buy
Buy
Analyst Count
26
22
Target Price
$167.65
$30.55
AVG Volume (30 Days)
928.5K
1.8M
Earning Date
05-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.12
EPS
N/A
0.02
Revenue
N/A
$726,437,000.00
Revenue This Year
$20.70
$18.80
Revenue Next Year
$16.48
$11.70
P/E Ratio
$34.38
$1,272.50
Revenue Growth
N/A
40.45
52 Week Low
$57.50
$19.69
52 Week High
$296.94
$28.35

Technical Indicators

Market Signals
Indicator
MNDY
ACAD
Relative Strength Index (RSI) 53.64 64.39
Support Level $67.84 $25.40
Resistance Level $88.48 $27.79
Average True Range (ATR) 4.12 0.93
MACD 1.00 0.05
Stochastic Oscillator 70.57 62.74

Price Performance

Historical Comparison
MNDY
ACAD

About MNDY monday.com Ltd.

Monday.com Ltd is an artificial intelligence work platform that runs and orchestrates the core of all work. The platform democratizes access to software, including AI, enabling organizations to easily build applications and work management tools that fit their needs. The cloud-based platform is a no-code and low-code framework built from modular building blocks that are simple enough for anyone to use, yet powerful enough to drive core business across any organization. The platform also integrates with other systems and applications, creating a connective layer for organizations that links departments and bridges information silos. In addition to the core products, it introduced four core Al work capabilities: monday sidekick, monday vibe, monday agents, and workflows.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: